Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2024-02-08 Interim / Quarterly Rep…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
FINAL RESULTS
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed financial results for the full year 2023 and Q4 2023, including revenue, EPS, segment performance, pipeline updates, regulatory approvals, and guidance for FY 2024. The document includes comprehensive financial data and analysis, not just a brief announcement or certification. Form 6-K filings typically serve as interim or quarterly reports for foreign private issuers. Given the detailed financial performance data and the nature of the filing, this document fits the definition of an Interim / Quarterly Report (IR).
2024-02-08 English
Final Results
Earnings Release Classification · 100% confidence The document text begins with 'National Storage Mechanism | Additional information RNS Number : 4058C AstraZeneca PLC 08 February 2024' and presents detailed financial summaries for 'FY 2023' and 'Q4 2023', including revenue, EPS, margin analysis, guidance for FY 2024, and pipeline updates. This structure is characteristic of a company releasing its full annual and quarterly financial results simultaneously. Since it contains comprehensive financial data for the full year (FY 2023) and the quarter (Q4 2023), it is more comprehensive than a simple Earnings Release (ER). While it is an announcement, the content is the core financial report itself, not just a notice of publication. Given the inclusion of full-year results, the most appropriate classification is Annual Report (10-K), although in many jurisdictions, this content might be released via an RNS/ER before the formal 10-K filing. However, based on the depth of financial tables covering the full year, 10-K is the closest fit among the options for comprehensive annual results reporting. If the document were strictly an announcement of the 10-K/IR being available, RPA would be chosen, but this text contains the results themselves. Q4 2023
2024-02-08 English
TOTAL VOTING RIGHTS
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the total voting rights as of a specific date (31 January 2024) and provides information relevant to shareholder notification requirements under the UK Financial Conduct Authority's Disclosure and Transparency Rules. The document is short (3169 characters) and primarily serves as a regulatory announcement of voting rights rather than a detailed report or financial statement. It does not contain financial results, management discussion, or detailed governance information. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-02-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official notification released via RNS (the news service of the London Stock Exchange), indicated by the 'RNS Number' and the closing boilerplate text. The content explicitly states the total number of issued shares with voting rights and the total number of voting rights as of a specific date (31 January 2024), referencing the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of filing, which reports on the total voting rights/capital structure, is a specific regulatory disclosure. While it relates to capital, it is not a financing announcement (CAP) or a major shareholding change (MRQ). Since it is a standard regulatory disclosure that doesn't fit perfectly into the other specific categories (like 10-K, ER, DIV), and it is clearly an RNS announcement, the most appropriate classification is the general regulatory filing category, RNS, as it is the source and nature of the communication.
2024-02-01 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-01-24 English
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the extension of a tender offer to acquire Icosavax, including regulatory filings related to the Hart-Scott-Rodino Antitrust Improvements Act, tender offer details, and forward-looking statements. The document is not a full financial report but rather an update on a capital transaction and related regulatory filings. It is not an earnings release, annual report, or management discussion. The content focuses on the tender offer extension and related merger process, which fits the category of Capital/Financing Update (CAP). The document length is substantial and contains substantive information about the financing activity, not just an announcement or a brief notice. Therefore, the appropriate classification is CAP with high confidence.
2024-01-19 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.